Health
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year data reinforce that majority of infants potentially exposed to OCREVUS during pregnancy or breastfeeding exhibit antibody responsesFenebrutinib two-year Phase II data demonstrate near-complete suppression of disease activity at 96 weeks Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TdqKHuoAMRswPfW7YQ22wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"OCREVUS subcutaneous maintains consistent benefit-risk profile after two years ","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMS","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"One-year data reinforce that majority of infants potentially exposed to OCREVUS during pregnancy or breastfeeding exhibit antibody responses","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Fenebrutinib two-year Phase II data demonstrate near-complete suppression of disease activity at 96 weeks","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":436,"olType":false},{"type":"text","content":"Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (24-26 September).","length":329,"tagName":"p"},{"type":"text","content":"New data show that treatment with OCREVUS provides significant benefit in preventing disability progression across diverse groups of people with multiple sclerosis (MS), including children with relapsing-remitting multiple sclerosis (RRMS), women with MS who are pregnant or breastfeeding, and adults with advanced primary progressive multiple sclerosis (PPMS). From Roche’s MS pipeline, Phase II data for fenebrutinib showing near-complete suppression of disease activity at 96 weeks will be presented ahead of upcoming pivotal study readouts.","length":544,"tagName":"p"},{"type":"text","content":""We have made significant scientific progress in th...